Exploring the Pharmaceutical Significance and Analytical Landscape of Ropinirole: An In-Depth Review of an Indole-Based Dopaminergic Therapeutic Agent.

Ropinirole, an indole-based dopamine agonist with high affinity for D2, D3, and D4 receptors, is widely used for Parkinson's disease (PD) and restless legs syndrome (RLS) due to its neuroprotective effects and ability to mitigate levodopa-induced motor complications. Despite well-established clinical efficacy and pharmacokinetics characterized by rapid absorption, hepatic metabolism via CYP1A2, and predominant renal excretion - comprehensive analytical profiling remains incomplete, particularly in stability-indicating methods, forced degradation studies, and impurity characterization. This review systematically evaluates ropinirole's pharmacological properties, formulation strategies (immediate-release [IR] and extended-release [ER]), and marketed products. It critically analyzes analytical methodologies, including HPLC, UHPLC (guided by Analytical Quality by Design [AQbD]), HPTLC, UV spectrophotometry, and LC-MS/MS, focusing on sensitivity, specificity, robustness, and regulatory compliance. HPLC dominates routine quantification, while UHPLC and LC-MS/MS excel in impurity profiling and pharmacokinetic studies. However, inconsistent reporting of forced degradation and stability assessments reveals critical gaps that hinder regulatory compliance and quality assurance. The indole moiety's influence on therapeutic action and analytical behavior underscores the need for tailored, validated methods addressing stability and impurities. Recommendations include developing robust stability-indicating protocols, implementing controlled stress testing, employing orthogonal techniques, and ensuring mass balance verification using advanced detectors and hyphenated tools. This review bridges pharmacological and analytical perspectives, advocating for next-generation platforms to enhance method sensitivity, selectivity, and reproducibility. Adopting validated, stability-indicating approaches will strengthen regulatory acceptance and improve therapeutic monitoring and quality control (QC) for ropinirole formulations.